Web Results

www.pacermonitor.com/public/case/22999479/Hartman_v_Janssen_Research__Development_LLC_et_al

Nov 15, 2017 ... Hartman v. Janssen Research & Development LLC et al (2:17-cv-12533), Louisiana Eastern District Court, Filed: 11/15/2017 - PacerMonitor Mobile Federal and Bankruptcy Court PACER Dockets.

www.pacermonitor.com/public/case/23417632/Robert_Marr,_et_al_v_Janssen_Research_and_Development_LLC_et_al

Jan 5, 2018 ... Robert Marr, et al v. Janssen Research and Development LLC et al (2:18-cv- 00109), California Central District Court, Filed: 01/05/2018 - PacerMonitor Mobile Federal and Bankruptcy Court PACER Dockets.

www.ncbi.nlm.nih.gov/pmc/articles/PMC5240065

[4,5,6] According to the recent data published in the Indian Council of Medical Research India Diabetes-3 study, the estimated prevalence of overweight and ..... Dr. William Canovatchel is an employee of Janssen Research and Development, LLC. ..... Schroeder M, Taieb V, Pacou M, Ho S, Nielsen AT, Schubert A, et al.

www.bloodjournal.org/content/bloodjournal/early/2015/07/31/blood-2015-03-632430.full.pdf

Jul 31, 2015 ... OFFNER et al. Upfront VR-CAP vs R-CHOP therapy for non-GCB DLBCL. 2. Offner Blood MS #BLOOD/2015/632430. Acknowledgment of research support for the study: This study was funded by. Janssen Research & Development, LLC. Corresponding author details: Professor Fritz Offner. Department of ...

www.bloodjournal.org/content/bloodjournal/126/16/1893.full.pdf

Oct 15, 2015 ... Raritan, NJ; 9Janssen Research & Development, LLC, Spring House, PA; 10Janssen Research & Development, Division of Janssen Pharmaceutica NV, ..... planned, requiring screening of ;364 patients based on the assumption that the non-GCB subtype constitutes ;45% of all DLBCL. 1894. OFFNER et al.